| Darin Gambles, DPM | |
|
1495 Parkway Dr, Ste B, Blackfoot, ID 83221-1638 | |
| (208) 785-2555 | |
| (208) 785-9952 |
| Full Name | Darin Gambles |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 29 Years |
| Location | 1495 Parkway Dr, Blackfoot, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790768174 | NPI | - | NPPES |
| 800772179 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | P153 (Idaho) | Primary |
| Provider Name | Darin Gambles |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1558633628 PECOS PAC ID: 2961660832 Enrollment ID: O20120223000223 |
News Archive
MAP Pharmaceuticals, Inc. today announced the publication of results from the Phase 3 FREEDOM-301 study of LEVADEX orally inhaled migraine drug in the peer-reviewed journal 'Headache.'
A new statistical method that can estimate the origin and time of an aerosolized release of the pathogen causing anthrax, following detection of the first few cases has been developed by researchers from the Medical Research Council (MRC) Centre for Outbreak Analysis and Modelling at Imperial College London in collaboration with the Health Protection Agency's Microbial Risk Assessment group.
Obesity is either caused by an increase in energy intake, or reduced energy expenditure, or both. However, it is difficult to state with certainty the cause of obesity.
Great Lakes NeuroTechnologies Secures Over $4.5 Million in Funding to Fuel New Product Development for Parkinson's Disease and Neuroscience Education April 24, 2012: Valley View, OH - Great Lakes NeuroTechnologies announced today they have secured over $4.5 million is funding for new product development. The funding includes three new projects sponsored by the National Institutes of Health's SBIR program. Each project is focused on developing and testing innovative neurotechnology. Two projects focus on the monitoring and treatment of Parkinson's disease while another will develop a wireless physiological monitor and web-based teaching system for high school neuroscience courses.
FLUIDDA's breakthrough imaging technology was used to assess the mode of action of Roflumilast, a novel drug to treat patients suffering from chronic obstructive pulmonary disease (COPD).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Darin Gambles, DPM 1495 Parkway Dr, Ste B, Blackfoot, ID 83221-1638 Ph: (208) 785-2555 | Darin Gambles, DPM 1495 Parkway Dr, Ste B, Blackfoot, ID 83221-1638 Ph: (208) 785-2555 |
News Archive
MAP Pharmaceuticals, Inc. today announced the publication of results from the Phase 3 FREEDOM-301 study of LEVADEX orally inhaled migraine drug in the peer-reviewed journal 'Headache.'
A new statistical method that can estimate the origin and time of an aerosolized release of the pathogen causing anthrax, following detection of the first few cases has been developed by researchers from the Medical Research Council (MRC) Centre for Outbreak Analysis and Modelling at Imperial College London in collaboration with the Health Protection Agency's Microbial Risk Assessment group.
Obesity is either caused by an increase in energy intake, or reduced energy expenditure, or both. However, it is difficult to state with certainty the cause of obesity.
Great Lakes NeuroTechnologies Secures Over $4.5 Million in Funding to Fuel New Product Development for Parkinson's Disease and Neuroscience Education April 24, 2012: Valley View, OH - Great Lakes NeuroTechnologies announced today they have secured over $4.5 million is funding for new product development. The funding includes three new projects sponsored by the National Institutes of Health's SBIR program. Each project is focused on developing and testing innovative neurotechnology. Two projects focus on the monitoring and treatment of Parkinson's disease while another will develop a wireless physiological monitor and web-based teaching system for high school neuroscience courses.
FLUIDDA's breakthrough imaging technology was used to assess the mode of action of Roflumilast, a novel drug to treat patients suffering from chronic obstructive pulmonary disease (COPD).
› Verified 3 days ago
Dan Earl Robinson, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 98 Poplar St, Blackfoot, ID 83221 Phone: 208-690-0394 | |
Advanced Foot & Ankle Center, Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 9 Airport Rd, Blackfoot, ID 83221 Phone: 208-785-6700 Fax: 208-785-6767 | |
Parkway Foot & Ankle Podiatrist Medicare: Medicare Enrolled Practice Location: 1495 Parkway Dr, Suite B, Blackfoot, ID 83221 Phone: 208-785-2555 Fax: 208-785-9952 | |
Douglas Stanley Williams, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 9 Airport Rd, Blackfoot, ID 83221 Phone: 208-785-6700 Fax: 208-785-6767 |